Scholars@Duke

• Background
• 

  Education, Training, & Certifications

  • Fellowship, Medical Oncology, Yale University 2006 - 2009
  • Residency, Internal Medicine, Penn State Milton S. Hershey Medical Center 2002 - 2005
  • D.O., New York Institute of Technology, College of Osteopathic Medicine 2001
• Expertise
• 

  Subject Headings

  • Bladder--Cancer--Adjuvant treatment
  • Bladder--Cancer--Chemotherapy
  • Bladder--Cancer--Diagnosis
  • Bladder--Cancer--Immunotherapy--Congresses
  • Bladder--Cancer--Treatment--Congresses
  • Cancer
  • Cancer Vaccines
  • Interleukin-2
  • Kidneys--Cancer--Chemotherapy--Congresses
  • Kidneys--Cancer--Immunotherapy
  • Kidneys--Cancer--Patients--United States
  • Nanoparticles
  • Nanotechnology
• Research
• 

  Selected Grants

  • An open-label, randomized, controlled phase 3 study of enfortumab vedotin in combination with pembrolizumab with or without chemotherapy, versus chemotherapy alone in previously untreated locally advanced or metastatic urothelial cancer awarded by Seattle Genetics, Inc 2020 - 2025
  • Targeted immuno-nanoparticles for directing antitumor immune response against breast cancer metastasis awarded by Case Western Reserve University 2020 - 2021
• 

  External Relationships

  • 2bPrecise
  • Bristol Myers Squibb
  • Eisai
  • Genentech
  • Merck & Co. USA (not assoc'd with Merck KGaA)
  • Seattle Genetics
• Publications & Artistic Works
• 

  Selected Publications

  • Academic Articles

    • Powers, Eric, Georgia Sofia Karachaliou, Chester Kao, Michael R. Harrison, Christopher J. Hoimes, Daniel J. George, Andrew J. Armstrong, and Tian Zhang. “Novel therapies are changing treatment paradigms in metastatic prostate cancer.” J Hematol Oncol 13, no. 1 (October 28, 2020): 144. https://doi.org/10.1186/s13045-020-00978-z.
       Full Text  Link to Item
    • Shieh, Alice C., Ezgi Guler, David Pfau, Ethan Radzinsky, Daniel A. Smith, Christopher Hoimes, Nikhil H. Ramaiya, and Sree Harsha Tirumani. “Imaging and clinical manifestations of immune checkpoint inhibitor-related colitis in cancer patients treated with monotherapy or combination therapy.” Abdom Radiol (Ny) 45, no. 10 (October 2020): 3028–35. https://doi.org/10.1007/s00261-019-02334-3.
       Full Text  Link to Item
    • Ansari-Gilani, Kianoush, Sree Harsha Tirumani, Daniel A. Smith, Ariel Nelson, Asrar Alahmadi, Christopher J. Hoimes, and Nikhil H. Ramaiya. “Myocarditis associated with immune checkpoint inhibitor therapy: a case report of three patients.” Emerg Radiol 27, no. 4 (August 2020): 455–60. https://doi.org/10.1007/s10140-020-01765-6.
       Full Text  Link to Item
    • Miller, Natalie J., Ali Raza Khaki, Leonidas N. Diamantopoulos, Mehmet A. Bilen, Victor Santos, Neeraj Agarwal, Rafael Morales-Barrera, et al. “Histological Subtypes and Response to PD-1/PD-L1 Blockade in Advanced Urothelial Cancer: A Retrospective Study.” J Urol 204, no. 1 (July 2020): 63–70. https://doi.org/10.1097/JU.0000000000000761.
       Full Text  Link to Item
    • Khaki, Ali Raza, Ang Li, Leonidas N. Diamantopoulos, Mehmet A. Bilen, Victor Santos, John Esther, Rafael Morales-Barrera, et al. “Impact of performance status on treatment outcomes: A real-world study of advanced urothelial cancer treated with immune checkpoint inhibitors.” Cancer 126, no. 6 (March 15, 2020): 1208–16. https://doi.org/10.1002/cncr.32645.
       Full Text  Link to Item
    • Flaig, Thomas W., Philippe E. Spiess, Neeraj Agarwal, Rick Bangs, Stephen A. Boorjian, Mark K. Buyyounouski, Sam Chang, et al. “Bladder Cancer, Version 3.2020, NCCN Clinical Practice Guidelines in Oncology.” J Natl Compr Canc Netw 18, no. 3 (March 2020): 329–54. https://doi.org/10.6004/jnccn.2020.0011.
       Full Text  Link to Item
    • Antonarakis, Emmanuel S., Josep M. Piulats, Marine Gross-Goupil, Jeffrey Goh, Kristiina Ojamaa, Christopher J. Hoimes, Ulka Vaishampayan, et al. “Pembrolizumab for Treatment-Refractory Metastatic Castration-Resistant Prostate Cancer: Multicohort, Open-Label Phase II KEYNOTE-199 Study.” J Clin Oncol 38, no. 5 (February 10, 2020): 395–405. https://doi.org/10.1200/JCO.19.01638.
       Full Text  Link to Item
    • “Novel MYC-Targeting Drug Is Effective in Mouse Prostate Cancer Models.” Cancer Discovery 10, no. 1 (January 2020): 15. https://doi.org/10.1158/2159-8290.cd-rw2019-167.
       Full Text
    • Atukorale, Prabhani U., Shruti P. Raghunathan, Vanitha Raguveer, Taylor J. Moon, Carolyn Zheng, Peter A. Bielecki, Michelle L. Wiese, et al. “Nanoparticle Encapsulation of Synergistic Immune Agonists Enables Systemic Codelivery to Tumor Sites and IFNβ-Driven Antitumor Immunity.” Cancer Res 79, no. 20 (October 15, 2019): 5394–5406. https://doi.org/10.1158/0008-5472.CAN-19-0381.
       Full Text  Link to Item
    • Sadeghi, Sarmad, Susan G. Groshen, Denice D. Tsao-Wei, Rahul Parikh, Amir Mortazavi, Tanya B. Dorff, Cheryl Kefauver, et al. “Phase II California Cancer Consortium Trial of Gemcitabine-Eribulin Combination in Cisplatin-Ineligible Patients With Metastatic Urothelial Carcinoma: Final Report (NCI-9653).” J Clin Oncol 37, no. 29 (October 10, 2019): 2682–88. https://doi.org/10.1200/JCO.19.00861.
       Full Text  Link to Item
    • Pal, Sumanta K., Andres Forero-Torres, John A. Thompson, John C. Morris, Saurabh Chhabra, Christopher J. Hoimes, Nicholas J. Vogelzang, et al. “A phase 1 trial of SGN-CD70A in patients with CD70-positive, metastatic renal cell carcinoma.” Cancer 125, no. 7 (April 1, 2019): 1124–32. https://doi.org/10.1002/cncr.31912.
       Full Text  Link to Item
    • Thompson, John A., Bryan J. Schneider, Julie Brahmer, Stephanie Andrews, Philippe Armand, Shailender Bhatia, Lihua E. Budde, et al. “Management of Immunotherapy-Related Toxicities, Version 1.2019.” J Natl Compr Canc Netw 17, no. 3 (March 1, 2019): 255–89. https://doi.org/10.6004/jnccn.2019.0013.
       Full Text  Link to Item
    • Beltran, Himisha, Clara Oromendia, Daniel C. Danila, Bruce Montgomery, Christopher Hoimes, Russell Z. Szmulewitz, Ulka Vaishampayan, et al. “A Phase II Trial of the Aurora Kinase A Inhibitor Alisertib for Patients with Castration-resistant and Neuroendocrine Prostate Cancer: Efficacy and Biomarkers.” Clin Cancer Res 25, no. 1 (January 1, 2019): 43–51. https://doi.org/10.1158/1078-0432.CCR-18-1912.
       Full Text  Link to Item
    • Le Tourneau, Christophe, Christopher Hoimes, Corrine Zarwan, Deborah J. Wong, Sebastian Bauer, Rainer Claus, Martin Wermke, et al. “Avelumab in patients with previously treated metastatic adrenocortical carcinoma: phase 1b results from the JAVELIN solid tumor trial.” J Immunother Cancer 6, no. 1 (October 22, 2018): 111. https://doi.org/10.1186/s40425-018-0424-9.
       Full Text  Open Access Copy  Link to Item
    • Hoimes, C. J., C. Albany, J. Hoffman-Censits, M. T. Fleming, E. Trabulsi, J. Picus, C. Cary, et al. “A phase Ib/II study of neoadjuvant pembrolizumab (pembro) and chemotherapy for locally advanced urothelial cancer (UC).” Annals of Oncology : Official Journal of the European Society for Medical Oncology 29 (October 1, 2018): viii726. https://doi.org/10.1093/annonc/mdy424.039.
       Full Text
    • Long, G. V., M. Milhem, A. Amin, C. J. Hoimes, T. Medina, R. M. Conry, C. Lao, et al. “Phase Ib/II, open label, multicenter, study of the combination of SD-101 and pembrolizumab in patients with advanced melanoma who are naïve to anti-PD-1 therapy.” Annals of Oncology : Official Journal of the European Society for Medical Oncology 29 (October 1, 2018): viii736. https://doi.org/10.1093/annonc/mdy424.055.
       Full Text
    • Ribas, A., I. Mehmi, T. Medina, C. Lao, S. Kummar, A. Amin, S. Deva, et al. “Phase Ib/II study of the combination of SD-101 and pembrolizumab in patients with advanced melanoma who had progressive disease on or after prior anti-PD-1 therapy.” Ann Oncol 29 Suppl 8 (October 2018): viii451–52. https://doi.org/10.1093/annonc/mdy289.021.
       Full Text  Link to Item
    • Tzeng, Alice, C Marcela Diaz-Montero, Patricia A. Rayman, Jin S. Kim, Paul G. Pavicic, James H. Finke, Pedro C. Barata, et al. “Immunological Correlates of Response to Immune Checkpoint Inhibitors in Metastatic Urothelial Carcinoma.” Target Oncol 13, no. 5 (October 2018): 599–609. https://doi.org/10.1007/s11523-018-0595-9.
       Full Text  Link to Item
    • Flaig, Thomas W., Philippe E. Spiess, Neeraj Agarwal, Rick Bangs, Stephen A. Boorjian, Mark K. Buyyounouski, Tracy M. Downs, et al. “NCCN Guidelines Insights: Bladder Cancer, Version 5.2018.” J Natl Compr Canc Netw 16, no. 9 (September 2018): 1041–53. https://doi.org/10.6004/jnccn.2018.0072.
       Full Text  Link to Item
    • Kang, Kylie H., William Grubb, Komal Sawlani, Michael K. Gibson, Christopher J. Hoimes, Lisa R. Rogers, Pierre Lavertu, and Min Yao. “Immune checkpoint-mediated myositis and myasthenia gravis: A case report and review of evaluation and management.” Am J Otolaryngol 39, no. 5 (September 2018): 642–45. https://doi.org/10.1016/j.amjoto.2018.06.003.
       Full Text  Link to Item
    • Ornstein, Moshe C., Claudia Marcela Diaz-Montero, Patricia Rayman, Paul Elson, Samuel Haywood, James H. Finke, Jin S. Kim, et al. “Myeloid-derived suppressors cells (MDSC) correlate with clinicopathologic factors and pathologic complete response (pCR) in patients with urothelial carcinoma (UC) undergoing cystectomy.” Urol Oncol 36, no. 9 (September 2018): 405–12. https://doi.org/10.1016/j.urolonc.2018.02.018.
       Full Text  Link to Item
    • Agarwal, Neeraj, Sumanta K. Pal, Andrew W. Hahn, Roberto H. Nussenzveig, Gregory R. Pond, Sumati V. Gupta, Jue Wang, et al. “Characterization of metastatic urothelial carcinoma via comprehensive genomic profiling of circulating tumor DNA.” Cancer 124, no. 10 (May 15, 2018): 2115–24. https://doi.org/10.1002/cncr.31314.
       Full Text  Link to Item
    • Rosenberg, Jonathan E., Noah M. Hahn, Meredith M. Regan, Lillian Werner, Ajjai Alva, Saby George, Joel Picus, et al. “Apatorsen plus docetaxel versus docetaxel alone in platinum-resistant metastatic urothelial carcinoma (Borealis-2).” Br J Cancer 118, no. 11 (May 2018): 1434–41. https://doi.org/10.1038/s41416-018-0087-9.
       Full Text  Link to Item
    • Spiess, Philippe E., Neeraj Agarwal, Rick Bangs, Stephen A. Boorjian, Mark K. Buyyounouski, Peter E. Clark, Tracy M. Downs, et al. “Bladder Cancer, Version 5.2017, NCCN Clinical Practice Guidelines in Oncology.” J Natl Compr Canc Netw 15, no. 10 (October 2017): 1240–67. https://doi.org/10.6004/jnccn.2017.0156.
       Full Text  Link to Item
    • Powles, Thomas, Peter H. O’Donnell, Christophe Massard, Hendrik-Tobias Arkenau, Terence W. Friedlander, Christopher J. Hoimes, Jae Lyun Lee, et al. “Efficacy and Safety of Durvalumab in Locally Advanced or Metastatic Urothelial Carcinoma: Updated Results From a Phase 1/2 Open-label Study.” Jama Oncol 3, no. 9 (September 14, 2017): e172411. https://doi.org/10.1001/jamaoncol.2017.2411.
       Full Text  Link to Item
    • Beltran, H., D. Danila, B. Montgomery, R. Szmulewitz, U. Vaishampayan, A. Armstrong, M. Stein, et al. “A phase 2 study of the aurora kinase A inhibitor alisertib for patients with neuroendocrine prostate cancer (NEPC).” Annals of Oncology 27 (October 1, 2016): vi565. https://doi.org/10.1093/annonc/mdw435.21.
       Full Text
    • Clark, Peter E., Philippe E. Spiess, Neeraj Agarwal, Rick Bangs, Stephen A. Boorjian, Mark K. Buyyounouski, Jason A. Efstathiou, et al. “NCCN Guidelines Insights: Bladder Cancer, Version 2.2016.” J Natl Compr Canc Netw 14, no. 10 (October 2016): 1213–24. https://doi.org/10.6004/jnccn.2016.0131.
       Full Text  Link to Item
    • Antunes, Jacob, Satish Viswanath, Mirabela Rusu, Laia Valls, Christopher Hoimes, Norbert Avril, and Anant Madabhushi. “Radiomics Analysis on FLT-PET/MRI for Characterization of Early Treatment Response in Renal Cell Carcinoma: A Proof-of-Concept Study.” Transl Oncol 9, no. 2 (April 2016): 155–62. https://doi.org/10.1016/j.tranon.2016.01.008.
       Full Text  Link to Item
    • Kiechle, Jonathan E., Robert Abouassaly, Cary P. Gross, Shan Dong, Edward E. Cherullo, Hui Zhu, Quoc-Dien Trinh, et al. “Racial Disparities in Partial Nephrectomy Persist Across Hospital Types: Results From a Population-based Cohort.” Urology 90 (April 2016): 69–74. https://doi.org/10.1016/j.urology.2015.10.035.
       Full Text  Link to Item
    • Hoimes, Christopher J., and Anant Madabhushi. “Editorial Comment.” Urology 88 (February 2016): 132–33. https://doi.org/10.1016/j.urology.2015.09.043.
       Full Text  Link to Item
    • Oliveira, Guilherme H., Sadeer G. Al-Kindi, Christopher Hoimes, and Soon J. Park. “Characteristics and Survival of Malignant Cardiac Tumors: A 40-Year Analysis of >500 Patients.” Circulation 132, no. 25 (December 22, 2015): 2395–2402. https://doi.org/10.1161/CIRCULATIONAHA.115.016418.
       Full Text  Link to Item
    • Peiris, Pubudu M., Aaron Abramowski, James Mcginnity, Elizabeth Doolittle, Randall Toy, Ramamurthy Gopalakrishnan, Shruti Shah, et al. “Treatment of Invasive Brain Tumors Using a Chain-like Nanoparticle.” Cancer Res 75, no. 7 (April 1, 2015): 1356–65. https://doi.org/10.1158/0008-5472.CAN-14-1540.
       Full Text  Link to Item
    • Toy, Randall, Lisa Bauer, Christopher Hoimes, Ketan B. Ghaghada, and Efstathios Karathanasis. “Targeted nanotechnology for cancer imaging.” Adv Drug Deliv Rev 76 (September 30, 2014): 79–97. https://doi.org/10.1016/j.addr.2014.08.002.
       Full Text  Link to Item
    • Deng, Yang, Jennifer K. Saucier-Sawyer, Christopher J. Hoimes, Junwei Zhang, Young-Eun Seo, Jillian W. Andrejecsk, and W Mark Saltzman. “The effect of hyperbranched polyglycerol coatings on drug delivery using degradable polymer nanoparticles.” Biomaterials 35, no. 24 (August 2014): 6595–6602. https://doi.org/10.1016/j.biomaterials.2014.04.038.
       Full Text  Link to Item
    • Valls, Laia, Christopher Hoimes, Andrew Sher, Lingzhi Hu, Zhenghong Lee, Raymond Muzic, and Norbert Avril. “Early response monitoring of receptor tyrosine kinase inhibitor therapy in metastatic renal cell carcinoma using [F-18]fluorothymidine-positron emission tomography-magnetic resonance.” Semin Roentgenol 49, no. 3 (July 2014): 238–41. https://doi.org/10.1053/j.ro.2014.09.001.
       Full Text  Link to Item
    • Martin, Darryl T., Christopher J. Hoimes, Hristos Z. Kaimakliotis, Christopher J. Cheng, Ke Zhang, Jingchun Liu, Marcia A. Wheeler, et al. “Nanoparticles for urothelium penetration and delivery of the histone deacetylase inhibitor belinostat for treatment of bladder cancer.” Nanomedicine 9, no. 8 (November 2013): 1124–34. https://doi.org/10.1016/j.nano.2013.05.017.
       Full Text  Link to Item
    • Fields, Rachel J., Christopher J. Cheng, Elias Quijano, Caroline Weller, Nina Kristofik, Nha Duong, Christopher Hoimes, Marie E. Egan, and W Mark Saltzman. “Surface modified poly(β amino ester)-containing nanoparticles for plasmid DNA delivery.” J Control Release 164, no. 1 (November 28, 2012): 41–48. https://doi.org/10.1016/j.jconrel.2012.09.020.
       Full Text  Link to Item
    • Hoimes, Christopher J., Megan K. Selbst, Nelofar Q. Shafi, Michal G. Rose, and Manuel F. Rosado. “Hodgkin's lymphoma of the breast.” J Clin Oncol 28, no. 2 (January 10, 2010): e11–13. https://doi.org/10.1200/JCO.2009.23.1613.
       Full Text  Link to Item
    • Hoimes, C. J., and W. K. Kelly. “Redefining hormone resistance in prostate cancer.” Therapeutic Advances in Medical Oncology 2, no. 2 (January 1, 2010): 107–23. https://doi.org/10.1177/1758834009356433.
       Full Text
    • Strimpakos, A. S., C. Hoimes, K. N. Syrigos, and M. W. Saif. “Pancreatic cancer and personalized medicine: Can genomics facilitate early diagnosis or improve therapeutic outcomes?” Current Pharmacogenomics and Personalized Medicine 8, no. 1 (January 1, 2010): 73–88. https://doi.org/10.2174/1875692111008010073.
       Full Text
    • Merl, My, Cj Hoimes, T. Pham, and M Wasif Saif. “Is there a palliative benefit of gemcitabine plus fluoropyrimidines in patients with refractory colorectal cancer? A review of the literature previously presented: poster at the 2008 Gastrointestinal Cancer Symposium (Abstract No. 512).” Expert Opin Investig Drugs 18, no. 9 (September 2009): 1257–64. https://doi.org/10.1517/13543780903136724.
       Full Text  Link to Item
    • Hoimes, Christopher J., Matthew T. Moyer, and Muhammad Wasif Saif. “Biomarkers for early detection and screening in pancreatic cancer. Highlights from the 45th ASCO annual meeting. Orlando, FL, USA. May 29-June 2, 2009.” Jop 10, no. 4 (July 6, 2009): 352–56.
       Link to Item
    • Hoimes, Christopher J., Alexios S. Strimpakos, and Muhammad Wasif Saif. “Therapeutic tools in pancreatic cancer.” Jop 10, no. 2 (March 9, 2009): 118–22.
       Link to Item
    • Strimpakos, Alexios S., Christopher Hoimes, and Muhammad Wasif Saif. “Pancreatic cancer: translating lessons from mouse models.” Jop 10, no. 2 (March 9, 2009): 98–103.
       Link to Item
    • Hoimes, C. J., and W. K. Kelly. “TROG 96.01: TTBF and PSAdt as surrogates for disease specific mortality.” Update on Cancer Therapeutics 3, no. 4 (January 1, 2009): 157–59. https://doi.org/10.1016/j.uct.2009.03.001.
       Full Text
    • Dodson, Cassidy, Daniel A. Smith, Tyler J. Richards, Robert R. Devita, Christopher J. Hoimes, and Nikhil H. Ramaiya. “Systemic Therapies for Melanoma Brain Metastases: A Primer for Radiologists.” J Comput Assist Tomogr 44, no. 3 (n.d.): 346–55. https://doi.org/10.1097/RCT.0000000000001006.
       Full Text  Link to Item
    • Liput, Joseph, Ezgi Guler, Daniel A. Smith, Sree Harsha Tirumani, Christopher Hoimes, Paolo F. Caimi, and Nikhil H. Ramaiya. “Clinical, Imaging Findings, Responses, and Outcomes of Patients With Classical Hodgkin Lymphoma and Non-Hodgkin Lymphoma Undergoing Immune Checkpoint Inhibitor Therapy: A Single-Institution Experience.” J Comput Assist Tomogr 44, no. 4 (n.d.): 619–26. https://doi.org/10.1097/RCT.0000000000001043.
       Full Text  Link to Item

  • Book Sections

    • Hoimes, C. J. “Antimicrotubule agents.” In DeVita, Hellman, and Rosenberg’s Cancer: Principles & Practice of Oncology, 288–97, 2018.
    • Hoimes, C. J., and L. N. Harris. “Antimicrotubule agents.” In DeVita, Hellman, and Rosenberg’s Cancer: Principles & Practice of Oncology: Tenth Edition, 2015.
    • Hoimes, C., G. Gibney, and W. K. Kelly. “Systemic therapy for advanced prostate cancer.” In Essentials and Updates in Urologic Oncology (2 Volume Set), 155–92, 2012.

  • Conference Papers

    • Ribas, Antoni, Mohammed M. Milhem, Christopher J. Hoimes, Asim Amin, Inderjit Mehmi, Christopher D. Lao, Robert Martin Conry, et al. “Phase 1b/2, open label, multicenter, study of the combination of SD-101 and pembrolizumab in patients with advanced melanoma who are naïve to anti-PD-1 therapy.” In Journal of Clinical Oncology, 36:9513–9513. American Society of Clinical Oncology (ASCO), 2018. https://doi.org/10.1200/jco.2018.36.15_suppl.9513.
       Full Text

Some information on this profile has been compiled automatically from Duke databases and external sources. (Our About page explains how this works.) If you see a problem with the information, please write to Scholars@Duke and let us know. We will reply promptly.